Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia

被引：0
|
作者：
Burnett, John R. [1 ]
机构：
[1] Royal Perth Hosp, Dept Core Clin Pathol & Biochem, PathW Lab Med WA, Perth, WA 6847, Australia
来源：
CURRENT OPINION IN MOLECULAR THERAPEUTICS | 2006年 / 8卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
ISIS-301012 is an antisense oligonucleotide inhibitor of apolipoprotein B-100, which is being developed by Isis Pharmaceuticals Inc for the potential treatment of hypercholesterolemia. A subcutaneous injectable formulation is currently undergoing phase II clinical trials, while phase I trials are underway with an oral formulation of the drug.
引用
收藏
页码：461 / 467
页数：7
相关论文
共 50 条
  • [41] The Role of Antisense Oligonucleotide Therapy in Patients with Familial Hypercholesterolemia: Risks, Benefits, and Management Recommendations
    Anandita Agarwala
    Peter Jones
    Vijay Nambi
    Current Atherosclerosis Reports, 2015, 17
  • [42] Renal uptake and tolerability of a 2′-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey
    Henry, Scott P.
    Johnson, Mark
    Zanardi, Thomas A.
    Fey, Robert
    Auyeung, Diana
    Lappin, Patrick B.
    Levin, Arthur A.
    TOXICOLOGY, 2012, 301 (1-3) : 13 - 20
  • [43] The ICAM-1 antisense oligonucleotide ISIS-3082 prevents the development of postoperative ileus in mice
    The, FO
    de Jonge, WJ
    Bennink, RJ
    van den Wijngaard, RM
    Boeckxstaens, GE
    BRITISH JOURNAL OF PHARMACOLOGY, 2005, 146 (02) : 252 - 258
  • [44] Pharmacokinetic drug evaluation of ezetimibe plus simvastatin for the treatment of hypercholesterolemia
    Bove, Marilisa
    Fogacci, Federica
    Cicero, Arrigo F. G.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (10) : 1099 - 1104
  • [45] ISIS 301012, an antisense inhibitor of apolipoprotein B, produces significant additional reduction of LDL-C and apolipoprotein B in hypercholesterolemic subjects on statins not meeting target
    Kastelein, John
    Akdim, Fatima
    Trip, Mieke
    Sijbrands, Eric
    Jukema, J. Wouter
    Bradley, Joann
    Wedel, Mark
    Su, John
    Chuang, Emil
    Stein, Evan
    Visseren, Frank
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (09) : 393A - 393A
  • [46] SIGNALING PATHWAY AS TARGET FOR DRUG DESIGN - ANTIMETASTATIC ANTISENSE OLIGONUCLEOTIDE
    ALMAHMOOD, S
    LUGASSY, C
    ESCANDE, JP
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1995, 105 (03) : 458 - 458
  • [47] The Antisense Oligonucleotide Nusinersen for Treatment of Spinal Muscular Atrophy
    Edinoff, Amber N.
    Nguyen, Long H.
    Odisho, Amira S.
    Maxey, Benjamin S.
    Pruitt, John W.
    Girma, Brook
    Cornett, Elyse M.
    Kaye, Adam M.
    Kaye, Alan D.
    ORTHOPEDIC REVIEWS, 2021, 13 (02)
  • [48] The effects of mipomersen, a second-generation antisense oligonucleotide, on atherogenic (apoB-containing) lipoproteins in the treatment of homozygous familial hypercholesterolemia
    McGowan, Mary P.
    Moriarty, Patrick M.
    Backes, James M.
    CLINICAL LIPIDOLOGY, 2014, 9 (05) : 487 - 503
  • [49] Evaluation of Isis Apo(a)Rx, an Antisense Inhibitor to Apolipoprotein(a), in Healthy Volunteers
    Viney, Nick
    Graham, Mark
    Crooke, Rosanne
    Hughes, Steve
    Singleton, Walter
    CIRCULATION, 2013, 128 (22)
  • [50] Antisense oligonucleotide and thyroid hormone conjugates for obesity treatment
    Cao, Yang
    Matsubara, Tomoko
    Zhao, Can
    Gao, Wei
    Peng, Linxiu
    Shan, Jinjun
    Liu, Zhengxia
    Yuan, Fang
    Tang, Lingyi
    Li, Peixin
    Guan, Zhibin
    Fang, Zhuyuan
    Lu, Xiang
    Huang, Hu
    Yang, Qin
    SCIENTIFIC REPORTS, 2017, 7
12345